Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Feb 03, 2023 8:57am
302 Views
Post# 35264371

RE:RE:Merck’s Keytruda brings in $21 Billion.

RE:RE:Merck’s Keytruda brings in $21 Billion. TDON ...  TLT's logo is "Destroying cancer at speed oflight".  So they are consistent with this.

And using the word "cure" is not what TLT's scientific platform does.  Destroying solid tumors is clearly more appropriate.  With individually invade each cancerous tumors with our PDC and then, when light activated, each of these cancerous cells die.

Curing means that you prevent the cancer to recure.  Immune protection from PDT is not strong enough to itself to guarantee this.

Destroying means that if, for whatever reasons,when a tumor pops up elsewhere, TLT would be able to destroying it.  Curing would mean that there would be no recurence, what so ever, from anywhere.

Regrading big pharmas, just like in any other industries, it's not easy to shift them.  It takes very precise circumstances to grow to a position of leader and TLT is not at this level.  At least, not now.  BioNTech's example was a good one as, in 2018, they had already been approached by Pfizer for an influenza mRNA vaccine.  Then, the opportunity with COVID-19 happened, then they signed a 3rd collaboration with Pfizer, this time against shingles  

So lets first sign a jv against NMIBC.  Then prove that we can repeat efficacy in GBM and NSCLC.  Dr. McFarland's approach is not one PDC for all cancers but rather one PDC specifically designed for a specific indication.  That's exactly what she posted on her web page.
<< Previous
Bullboard Posts
Next >>